Breast cancer is a disease characterized by the abnormal proliferation of cells originating in the epithelial tissue of the breast. It is the most commonly diagnosed malignant tumor among women globally, as well as in China. According to the data released by the International Agency for Research on Cancer (IARC) in 2024, there were approximately 2.31 million new cases of breast cancer worldwide in 2022, with 357,000 new cases in China, posing a serious threat to patients' physical and mental health.
Despite the continuously rising incidence rate, breast cancer is both preventable and treatable. Lifestyle improvements such as weight management, regular exercise, reduced hormone exposure, and limiting alcohol intake can help lower the risk. Moreover, the principle of "early detection, early diagnosis, and early treatment" is key to achieving long-term survival and a better quality of life for patients.
October is globally recognized as World Breast Cancer Awareness Month, with October 18th designated as Breast Cancer Awareness Day. This global initiative, advocated by the World Health Organization, aims to raise public awareness of breast diseases and promote scientific prevention and timely intervention.
Alphamab Oncology has been closely focused on addressing unmet clinical needs in oncology, committed to providing breakthrough innovative therapeutics for patients. In the field of breast cancer, the company’s independently developed HER2 bispecific antibody anbenitamab injection (KN026), can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. Compared with trastuzumab and pertuzumab in combination, anbenitamab has demonstrated better tumor inhibition in HER2-positive tumor cells. Currently, two Phase III clinical studies of anbenitamab for first-line treatment and neoadjuvant therapy of HER2-positive breast cancer are steadily progressing.
Alphamab Oncology's next-generation HER2 biparatopic antibody-drug conjugate (ADC), JSKN003, is built upon anbenitamab and advances the precision medicine approach. It demonstrates superior serum stability, enhanced bystander effect, and a favorable safety profile, compared to similar ADCs, positioning it as a promising new treatment for HER2-expressing breast cancer. Currently, two Phase III clinical studies of JSKN003 for HER2-low breast cancer and HER2-positive breast cancer are also proceeding smoothly.
Moving forward, under the guidance of the "Healthy China 2030" strategy, Alphamab Oncology will continue to leverage its leading proprietary technology platforms to expand product pipeline with significant differentiated advantages. The company is committed to deepening innovation in drug development and exploring combination therapies for breast cancer, contributing technological strength to global health.
About Alphamab Oncology
Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK).
Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
